HomeCHEOY • OTCMKTS
add
Cochlear Ord ADR
Previous close
$99.58
Day range
$99.37 - $99.64
Year range
$74.76 - $105.60
Market cap
19.61B AUD
Avg Volume
3.85K
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
| (AUD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 585.65M | 3.01% |
Operating expense | 301.25M | -1.25% |
Net income | 91.90M | 11.12% |
Net profit margin | 15.69 | 7.84% |
Earnings per share | — | — |
EBITDA | 129.05M | 2.26% |
Effective tax rate | 24.11% | — |
Balance Sheet
Total assets
Total liabilities
| (AUD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 275.70M | -46.32% |
Total assets | 2.82B | 2.91% |
Total liabilities | 874.70M | -3.31% |
Total equity | 1.95B | — |
Shares outstanding | 65.40M | — |
Price to book | 3.34 | — |
Return on assets | 11.11% | — |
Return on capital | 14.36% | — |
Cash Flow
Net change in cash
| (AUD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 91.90M | 11.12% |
Cash from operations | 63.85M | -44.89% |
Cash from investing | -32.00M | -10.54% |
Cash from financing | -84.70M | -15.71% |
Net change in cash | -53.70M | -478.17% |
Free cash flow | 81.81M | -2.56% |
About
Cochlear is a medical device company that designs, manufactures, and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant.
Based in Sydney, Cochlear was formed in 1981 as a subsidiary of Nucleus with finance from the Australian government to commercialise the implants pioneered by Dr. Graeme Clark, although the company later became separate. As of 2022, the company holds 50% of the cochlear implant market, with more than 250,000 people receiving one of Cochlear's implants as of 2015.
Cochlear was named Australia's most innovative company by the Intellectual Property Research Institute of Australia in 2002 and 2003, and one of the world's most innovative companies by Forbes in 2011. Wikipedia
CEO
Founded
1981
Headquarters
Website
Employees
5,500
